Cigna Group: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 5, 2023 and accepted by EDGAR at May 5, 2023, 10:50 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $46.52bn | us-gaap:Revenues |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $31.46bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $3.54bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | $2.02bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $295.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | $1.31bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | $4.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | $4.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 298,999,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | $5.03bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 3 months2023-01-01 to 2023-03-31 | $368.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2023-01-01 to 2023-03-31 | $962.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-03-31 | $7.93bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $32.03bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $147.98bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $44.73bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $103.38bn | us-gaap:Liabilities |
| Current portion of debt | At period end2023-03-31 | $3.42bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2023-03-31 | $44.50bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001739940-23-000016. Last ingested by Listed: Nov 5, 2026, 13:13 ET. Listed shows no prices and gives no investment advice.